MediTech Chronicles

  PRECISION MEDICINE:  Personalizing Healthcare with Genomics W hat if your doctor could prescribe a treatment that is tailored to your unique genetic makeup, lifestyle and environment? That is the promise of precision medicine, an emerging field that uses genomics and other data to create personalized healthcare plans. Precision medicine is not a new concept. For decades, doctors have been using blood type, allergies and other factors to customize treatments for patients. However, with the advances in genomic sequencing and data analysis, precision medicine has become more feasible and affordable than ever before. In the realm of healthcare, one size does not fit all. Each individual is unique, and so are their genetic makeup and health needs. Traditional medical practices have often employed a generalized approach to treatment, assuming that what works for one patient should work for another.  However, thanks to groundbreaking advancements in genomics, the landscape of ...

The healthcare industry stands at an inflection point.  Wearable medical devices have transitioned  from consumer novelties to clinical-grade tools, with the global market reaching USD 42.7 billion in 2024 and expected to exceed USD 152 billion by 2029, according to Grand View Research .  But the real story isn't the market size—it's the fundamental shift in how care is delivered. For the first time in medical history, continuous, non-invasive monitoring of patients outside clinical settings is becoming standard practice rather than exception. Remote patient monitoring (RPM) powered by IoT wearables is reducing hospital readmissions for chronic disease management, enabling early detection of acute episodes, and shifting healthcare from reactive treatment to proactive prevention. Healthcare systems implementing wearable-integrated workflows report significant improvements in patient outcomes and operational efficiency. The technological drivers are clear: advances in...

Demystifying AI in Drug Discovery: Transforming Pharma R&D Artificial Intelligence (AI) has swiftly transformed industries, and drug discovery is no exception.  The pharmaceutical research and development (R&D) process has traditionally been lengthy, resource-intensive, and marked by high failure rates. However, with the advent of AI, a new era has dawned, promising to revolutionize the drug discovery landscape.  This article delves into the nuances of AI in drug discovery , exploring how it's reshaping pharma R&D processes and accelerating the journey toward innovative therapies. 1. Understanding AI in Drug Discovery: AI refers to the simulation of human intelligence in machines, enabling them to perform tasks that typically require human cognition, such as learning, reasoning, and problem-solving.  In drug discovery, AI algorithms analyze vast datasets to identify patterns, predict outcomes, and generate insights that aid in the identification and developmen...

Sandoz boosts Canadian production capacity Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent. The plant, which is due to be fully operational by mid September, comprises manufacturing, laboratory and warehousing space that the firm believes will give it the flexibility it needs to keep pace with increasing market demands.  Richard Saynor, Head of Commercial Operations for Asia-Pacific, Latin America, Canada and Turkey says that: “The new plant in Boucherville is highly significant for our Canadian operations, and for Sandoz worldwide. It will enable us to triple our production capacity in both vials and ampoules.  The new plant will manufacture a range of medicines, including opiate analgesics. We currently make 85 different molecules in Boucherville and the plant supplies products globally, although the bulk of sales are in Canada and the US.

Cholesterol- lowering drug given cancer all-clear Cancer fears about a cholesterol- lowering drug have turned out to be a 'statistical blip'. A class of cholesterol- lowering drug that had been implicated in a cancer scare has been cleared by epidemiologists using the results from two large ongoing clinical trials.   Preliminary results from the relatively small SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study had triggered the cancer scare in July. The trial was designed to investigate whether a combination of these two cholesterol- lowering drugs would help in cases of aortic stenosis, where a key heart valve is partially blocked. Simvastatin, a statin that has already been used in other drugs, works by blocking cholesterol synthesis in the body. The newer ezetimibe works by blocking the absorption of cholesterol from the gut.  A unusual pre-publication announcement from the SEAS study reported that, while the therapy did not help very much in aortic stenosis, canc...

Big pharma's pre-competitive collaboration Merck, Eli Lilly and Pfizer have provided funding to launch Enlight Biosciences, a for-profit venture that aims to advance breakthrough technologies for drug discovery and development. The lowdown: There has recently been increasing emphasis from industry on participating in non-profit collaborations to address issues in drug development that are considered to be pre-competitive.  Now, Merck, Eli Lilly and Pfizer, together with the venture capital firm PureTech Ventures and several leading academic researchers, have founded Enlight Biosciences.  This is a for-profit venture that will aim to tackle critical unmet industry needs with innovations from academia and start-up companies. Enlight Biosciences, based in Boston, USA, will direct up to US$39 million into technologies that strengthen the connection between preclinical research, clinical research and post-market use, such as techniques that could help predict human responses to exp...